The German parent of Bayer MaterialScience, whose North American headquarters is in Robinson, announced Thursday it will spin off the unit in the next 12 to 18 months.
Bayer’s stock shot up by more than 6 percent on the Frankfurt stock exchange following the news, which has been predicted for months, if not years.
Speculation about a potential sale of the unit, which makes materials used in insulation foams, car seats and coatings, has been swirling for some time, as Bayer’s CEO Marijn Dekkers has made clear over the past several years that life sciences would be the company's driver going forward. That includes its HealthCare and CropScience divisions.
In April, Mr. Dekkers declined to answer questions about negotiations for a potential sale of MaterialSciences to another German company, Evonik Industries. Bloomberg News had reported then a deal may have been in the works.
Ultimately, as company leaders reiterated many times during a call with reporters on Thursday, Bayer wants the market to assign value to its MaterialScience assets, which have been growing over the past few years despite sluggish sales.
Bayer MaterialScience spokesman Bob Walker said details of how the spinoff will be accomplished, such as through an initial public offering of shares, have not been determined yet.
Read More
When Bayer separated its specialty chemicals business from the parent company in 2005 with the formation of Lanxess, shareholders received one share in the new company for every Bayer share they owned. Bayer decided to spin off the specialty chemical business in November 2003 and the process was completed in January 2005.
Since then, Lanxess shares have outperformed the S&P 500, generating annualized returns of nearly 13 percent, including dividends. Mr. Dekkers said Thursday that the upcoming split will give MaterialScience direct access to the capital markets, something the company will need to keep pace with a growing field of competitors.
MaterialScience has been a drag on Bayer's earnings in recent years.
The division “created headwind for our company,” Bayer’s last annual report said. “MaterialScience faced considerable challenges in 2013, in what remained a difficult market environment.”
While sales volumes remained stable over the past year, high raw material costs and somewhat lower prices drained pre-tax earnings by 15 percent.
Of Bayer’s three units, MaterialScience had the lowest cash flow return on investment, according to the company’s annual report, and was only one with negative cash value added.
“We are confident that in coming years, the return in MaterialScience will grow,” Mr. Dekkers said Thursday. “That means that the capital employed will be earned.”
That’s part of the reason Bayer decided to float the unit on the market, instead of selling it off, said Werner Baumann, the company’s CFO. “We’re doing this from a position of strength,” he said.
“While it’s maybe not a fit with Bayer’s portfolio, it’s actually among the better chemical businesses in that peer universe,” said Jason Miner, senior global chemicals analyst for Bloomberg Intelligence.
The company estimated that once the spinoff is complete, Bayer Group will employ 99,000 people, while the to-be-renamed MaterialScience entity will have 16,800 workers. Both will be headquartered in Leverkusen, Germany.
Bayer employs about 2,200 workers in the Pittsburgh region, of which 1,200 are at its Robinson campus and another 1,000 at a medical device business formerly known as Medrad. The company signed an agreement with its operations in Germany that there would be no layoffs before 2020. While it didn't mention anything analogous in the U.S., Mr. Dekkers told reporters on Thursday that he doesn't anticipate any changes to Bayer's presence in Pittsburgh in the near future.
“Pittsburgh is an important location for Bayer MaterialScience,” he said. “There’s no reason to assume that [the unit] will not continue its activities with this scope to support the North American market in the U.S. from Pittsburgh.”
Mr. Dekkers said he's also pleased with the work of the “significant number of health care employees” in this region and that there are no plans to move them to another U.S. city as a result of the restructuring.
Bayer’s net income last year was 3.2 billion euros ($4.13 billion) on revenue of 40 billion euros ($51.66 billion).
The MaterialScience division comprised 29 percent of last year's revenue but only 8 percent of operating income.
The majority of the unit's sales are in European markets, nearly twice as much as in the U.S, but the materials division has been beefing up its presence in Asia. It is expanding production capacity in Shanghai and plans to open a new manufacturing plant there in December.
It’s those kinds of heavy capital demands that inspired Bayer to look for a different funding mechanism for MaterialScience’s needs, executives said.
As both sides of the company mature, MaterialScience is often competing with its life science peers for investment dollars, “and those businesses are offering consistently better returns,” Mr. Dekkers said Thursday.
The materials science unit “is not always at the top of the agenda when it comes to investing,” he said.
Bayer expects to invest proceeds from the transaction into its healthcare business and to pay down debt.
The proposed split follows a “trend across basic chemicals for separating dissimilar businesses,” Bloomberg’s Mr. Miner said. “It’s something we’re seeing a lot of activist investors [push].”
Earlier this week, Nelson Peltz, founder of hedge fund Trian Partners, sent a public letter to DuPont urging a similar splintering of its business units.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.